

# Stanford

---

## Vishnu Shankar

Ph.D. Student in Immunology, admitted Autumn 2021

### Publications

---

#### PUBLICATIONS

- **Distinguishing Renal Cell Carcinoma From Normal Kidney Tissue Using Mass Spectrometry Imaging Combined With Machine Learning.** *JCO precision oncology*  
Shankar, V., Vijayalakshmi, K., Nolley, R., Sonn, G. A., Kao, C. S., Zhao, H., Wen, R., Eberlin, L. S., Tibshirani, R., Zare, R. N., Brooks, J. D.  
2023; 7: e2200668
- **Rationale for LDH-targeted cancer immunotherapy.** *European journal of cancer (Oxford, England : 1990)*  
Miholjcic, T. B., Halse, H., Bonvalet, M., Bigorgne, A., Rouanne, M., Dercle, L., Shankar, V., Marabelle, A.  
2022; 181: 166-178
- **Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self.** *Circulation research*  
Roy Chowdhury, R., D'Addabbo, J., Huang, X., Veizades, S., Sasagawa, K., Louis, D. M., Cheng, P., Sokol, J., Jensen, A., Tso, A., Shankar, V., Wendel, B. S., Bakerman, et al  
2022: 101161CIRCRESAHA121320090
- **SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.** *Cell reports. Medicine*  
Rice, M. A., Kumar, V., Tailor, D., Garcia-Marques, F. J., Hsu, E., Liu, S., Bermudez, A., Kanchustambham, V., Shankar, V., Inde, Z., Alabi, B. R., Muruganantham, A., Shen, et al  
2022; 3 (2): 100502
- **CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.** *Blood cancer discovery*  
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., Beygi, S., Kanegai, A. M., Corbelli, K. S., Gabriel, E., Kurtz, D. M., Khodadoust, M. S., Gupta, et al  
2022
- **Identification of end-stage renal disease metabolic signatures from human perspiration** *Natural Sciences*  
Shankar, V., Michael, B., Celli, A., Zhou, Z., Ashland, M., Tibshirani, R., Snyder, M., Zare, R.  
2022
- **An open repository of real-time COVID-19 indicators.** *Proceedings of the National Academy of Sciences of the United States of America*  
Reinhart, A., Brooks, L., Jahja, M., Rumack, A., Tang, J., Agrawal, S., Al Saeed, W., Arnold, T., Basu, A., Bien, J., Cabrera, Á. A., Chin, A., Chua, et al  
2021; 118 (51)
- **In situ DESI-MSI lipidomic profiles of mucosal margin of oral squamous cell carcinoma.** *EBioMedicine*  
Yang, X., Song, X., Zhang, X., Shankar, V., Wang, S., Yang, Y., Chen, S., Zhang, L., Ni, Y., Zare, R. N., Hu, Q.  
2021; 70: 103529
- **MassExplorer: a computational tool for analyzing desorption electrospray ionization mass spectrometry data** *Bioinformatics (Oxford, England)*  
Shankar, V., Tibshirani, R., Zare, R. N.  
2021
- **Oral squamous cell carcinoma diagnosed from saliva metabolic profiling.** *Proceedings of the National Academy of Sciences of the United States of America*  
Song, X., Yang, X., Narayanan, R., Shankar, V., Ethiraj, S., Wang, X., Duan, N., Ni, Y., Hu, Q., Zare, R. N.  
2020
- **Metabolite therapy guided by liquid biopsy proteomics delays retinal neurodegeneration.** *EBioMedicine*  
Wert, K. J., Velez, G. n., Kanchustambham, V. L., Shankar, V. n., Evans, L. P., Sengillo, J. D., Zare, R. N., Bassuk, A. G., Tsang, S. H., Mahajan, V. B.

2020; 52: 102636

- **Developing Successful Mental Illness Prevention Efforts on University Campuses: A Local Look Based on the CARES Program at Stanford University** *Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) Connect*  
Shankar, V., Albucher, R.  
2020
- **Identification of Diagnostic Metabolic Signatures in Clear Cell Renal Cell Carcinoma Using Mass Spectrometry Imaging.** *International journal of cancer*  
Vijayalakshmi, K., Shankar, V., Bain, R. M., Nolley, R., Sonn, G. A., Kao, C., Zhao, H., Tibshirani, R., Zare, R. N., Brooks, J. D.  
2019
- **The 3D Structure of Human DP Prostaglandin G-Protein-Coupled Receptor Bound to Cyclopentanoindole Antagonist, Predicted Using the DuplexBiHelix Modification of the GEnSeMBLE Method.** *Journal of chemical theory and computation*  
Shankar, V., Goddard, W. A., Kim, S. K., Abrol, R., Liu, F.  
2018; 14 (3): 1624-1642
- **Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis** *LANCET DIABETES & ENDOCRINOLOGY*  
Basu, S., Shankar, V., Yudkin, J. S.  
2016; 4 (11): 922-932